M. Kirshner

发表

Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women

M. Folan, B. Pollock, J. Stack, 1999, Journal of clinical pharmacology.

Anticholinergic Activity of 107 Medications Commonly Used by Older Adults

B. Pollock, B. Mulsant, R. Bies, 2008, Journal of the American Geriatrics Society.

•1-Acid Glycoprotein in Late-Life Depression: Relationship to Medical Burden and Genetics

B. Pollock, B. Mulsant, C. Reynolds, 2003, Journal of geriatric psychiatry and neurology.

Depression Subtypes in Pediatric Inflammatory Bowel Disease

D. Kupfer, A. Bousvaros, A. Youk, 2014, Journal of pediatric gastroenterology and nutrition.

Predictors of Depression in Youth With Crohn Disease

A. Bousvaros, A. Youk, E. Szigethy, 2014, Journal of pediatric gastroenterology and nutrition.

A Preliminary Study of the Effect of Fluoxetine Treatment on the 2:16-&agr;-Hydroxyestrone Ratio in Young Women

B. Pollock, T. Klug, K. Kastango, 2003, Therapeutic drug monitoring.

Pharmacokinetics of Single‐ and Multiple‐Dose Bupropion in Elderly Patients with Depression

B. Pollock, R. Sweet, C. DeVane, 1995, Journal of clinical pharmacology.

Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection.

D. Sorisio, M. Kirshner, J. Foglia, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline.

B. Pollock, B. Mulsant, C. Reynolds, 1998, The American journal of psychiatry.

A model of anticholinergic activity of atypical antipsychotic medications

B. Pollock, S. Kapur, B. Mulsant, 2006, Schizophrenia Research.

Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure

D. Kupfer, E. Frank, A. Fagiolini, 2010, Journal of clinical pharmacology.

Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.

B. Pollock, J. Brar, J. Levine, 2000, Journal of clinical psychopharmacology.

Antipsychotic Radioreceptor Assay: A Modification Identifying Selective Receptor Effects

R. Sweet, M. Kirshner, M. Demichele, 2001, Therapeutic drug monitoring.

Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease.

D. Kupfer, J. Weisz, A. Bousvaros, 2014, Journal of the American Academy of Child and Adolescent Psychiatry.

Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression

D. Kupfer, B. Pollock, B. Mulsant, 2000, Neuropsychopharmacology.

Quantitative determination of perphenazine and its metabolites in plasma by high-performance liquid chromatography and coulometric detection.

B. Mulsant, J. Perel, D. Sorisio, 1995, Journal of chromatography. B, Biomedical applications.

Sex, Race, and Smoking Impact Olanzapine Exposure

L. Schneider, S. Marder, R. Bies, 2008, Journal of clinical pharmacology.

Risperidone and 9-Hydroxyrisperidone Concentrations Are Not Dependent on Age or Creatinine Clearance among Elderly Subjects

B. Pollock, B. Mulsant, R. Sweet, 2002, Journal of geriatric psychiatry and neurology.

Pharmacologic profile of perphenazine's metabolites.

B H Mulsant, B. Pollock, B. Mulsant, 2000, Journal of clinical psychopharmacology.

Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance.

B. Pollock, B. Mulsant, H. Dodge, 2003, Archives of general psychiatry.

Serum anticholinergic activity and motor performance in elderly persons.

B. Pollock, P. Houck, R. Nebes, 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

Sophia Vinogradov, Christine Holland, Melissa Fisher, 2009, The American journal of psychiatry.

Population Pharmacokinetics of Perphenazine in Schizophrenia Patients From CATIE: Impact of Race and Smoking

J. Lieberman, L. Schneider, S. Marder, 2010, Journal of clinical pharmacology.

Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects

Vijay Dhawan, Yilong Ma, Maren Carbon, 2002, Synapse.

An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations.

B. Pollock, B. Mulsant, L. Burgio, 1997, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of Escitalopram

D. Kupfer, E. Frank, A. Fagiolini, 2009, Journal of clinical pharmacology.

Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients.

B. Pollock, B. Mulsant, C. Reynolds, 1997, Psychopharmacology bulletin.

Utility of Sparse Concentration Sampling for Citalopram in Elderly Clinical Trial Subjects

D. Kupfer, R. Bies, F. Lotrich, 2004, Journal of clinical pharmacology.

Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances.

B. Pollock, B. Mulsant, R. Bies, 2005, The American journal of geriatric pharmacotherapy.

S-mephenytoin 4-hydroxylation in older Americans

C. Reynolds, B. Pollock, J. Perel, 2004, European Journal of Clinical Pharmacology.

Plasma levels of citalopram enantiomers and metabolites in elderly patients.

B. Pollock, B. Mulsant, R. Sweet, 1997, Psychopharmacology bulletin.

Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.

B. Pollock, C. Reynolds III, F. Lotrich, 2008, Journal of psychiatry & neuroscience : JPN.

CYP2D6 Genotyping with Oligonucleotide Microarrays and Nortriptyline Concentrations in Geriatric Depression

B. Pollock, B. Mulsant, C. Reynolds, 2001, Neuropsychopharmacology.

Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.

B. Pollock, C. Reynolds, P. Houck, 1992, Psychopharmacology bulletin.

Predictors of Abdominal Pain in Depressed Pediatric Inflammatory Bowel Disease Patients

A. Bousvaros, A. Youk, E. Szigethy, 2014, Inflammatory bowel diseases.

Bupropion plasma levels and CYP2D6 phenotype.

B. Pollock, C. Reynolds, R. Sweet, 1996, Therapeutic drug monitoring.

Effect of Nortriptyline and Paroxetine on CYP2D6 Activity in Depressed Elderly Patients

B. Pollock, B. Mulsant, C. Reynolds, 2002, Journal of clinical psychopharmacology.